Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Biological Gender on Peripheral Nerve Blockade with Ropivacaine
2022-003201-30Phase 4Terminated
- Sponsor
- Medical University of Vienna
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of ropivacaine, sponsored by Medical University of Vienna. Primary endpoints: Pharmacodynamic differences by biological sex, Pharmacokinetic differences by biological sex and 1 more. Started Oct 2022; status: terminated.
02
Drugs
ropivacaine
Beyond the preview
Go deeper on 2022-003201-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003201-30.